Developing urinary metabolomic signatures as early bladder cancer diagnostic markers

OMICS A Journal of Integrative Biology

Volumn 19, Issue 1, 2015, Pages 1-11

  Shen, Chong ^a   Sun, Zeyu ^b,c   Chen, Deying ^b   Su, Xiaoling ^b   Jiang, Jing ^b   Li, Gonghui ^d   Lin, Biaoyang ^b,c,e   Yan, Jiajun ^a  

^a SHAOXING UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d ZHEJIANG UNIVERSITY   (China)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ASPARTYLASPARTYLGLYCYLTRYPTOPHINE; BIOLOGICAL MARKER; GLYCYLCYTEINYLALANYLLYSINE; INOSINE PHOSPHATE; NICOTINURIC ACID; SUCCINIC ACID; TREHALOSE; UNCLASSIFIED DRUG; UREIDOSUCCINIC ACID; TUMOR MARKER;

AGED; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; METABOLOMICS; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION; URINALYSIS; MIDDLE AGED; URINARY BLADDER NEOPLASMS; URINE;

AGED; BIOMARKERS, TUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; URINARY BLADDER NEOPLASMS;

EID: 84920775677     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2014.0116     Document Type: Article

References (23)

1. Budman LI, Kassouf W, and Steinberg JR. (2008). Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2, 212-221.
2. Chen L, and Pankiewicz KW. (2007). Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Devel 10, 403-412.
3. Erikssona L, Trygg J, and Wold S. (2008). CV-ANOVA for significance testing of PLS and OPLS models. J Chemometrics 22, 594-600.
4. Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, and Dimopoulos C. (2001). Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 166, 470-475.
5. Gronwald W, Klein MS, Zeltner R, et al. (2011). Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine. Kidney Int 79, 1244-1253.
6. Grossfeld GD, Litwin MS, Wolf JS, et al. (2001). Evaluation of asymptomatic microscopic hematuria in adults: The American Urological Association best practice policy-part I: Definition, detection, prevalence, and etiology. Urology 57, 599-603.
7. Huang Z, Lin L, Gao Y, et al. (2011). Bladder cancer determination via two urinary metabolites: A biomarker pattern approach. Mol Cell Proteomics 10, M111 007922.
8. Issaq HJ, Nativ O, Waybright T, et al. (2008). Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol 179, 2422-2426.
9. Jobu K, Sun C, Yoshioka S, et al. (2012). Metabolomics study on the biochemical profiles of odor elements in urine of human with bladder cancer. Biol Pharm Bull 35, 639-642.
10. Kaufman DS, Shipley WU, and Feldman AS. (2009). Bladder cancer. Lancet 374, 239-249.
11. Lozano R, Naghavi M, Foreman K, et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1 990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128.
12. Mahnert B, Tauber S, Kriegmair M, et al. (2003). Measurements of complement factor H-related protein (B TA-TRAK assay) and nuclear matrix protein (NMP22 assay)-Useful diagnostic tools in the diagnosis of urinary bladder cancer? Clin Chem Lab Med 41, 104-110.
13. Pasikanti KK, Esuvaranathan K, Ho PC, et al. (2010). Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res 9, 2988-2995.
14. Putluri N, Shojaie A, Vasu VT, et al. (2011). Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res 71, 7376-7386.
15. Shariat SF, Karam JA, Lotan Y, and Karakiewizc PI. (2008). Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 10, 120-135.
16. Siegel R Naishadham D Jemal A. 2012. Cancer statistics. 2012. CA Cancer J Clin 62 10-29.
17. Sreekumar A, Poisson LM, Rajendiran TM, et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914.
18. Srivastava S, Roy R, Singh S, et al. (2010). Taurine: A possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy. Cancer Biomark 6, 11-20.
19. Sullivan PS, Chan JB, Levin MR, and Rao J. (2010). Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res 2, 412-440.
20. Tetu B. (2009). Diagnosis of urothelial carcinoma from urine. Mod Pathol 22, S53-59.
21. Urquidi V, Rosser CJ, and Goodison S. (2012). Molecular diagnostic trends in urological cancer: Biomarkers for noninvasive diagnosis. Curr Med Chem 19, 3653-3663.
22. Van Kuilenburg AB , Van Lenthe H, Loffler M, and Van Gennip AH. (2004).Analysis of pyrimidine synthesis de novo intermediates in urine and dried urine filter-paper stripswith HPLC-electrospray tandem mass spectrometry. Clin Chem 50, 2117-2124.
23. Vrooman OP, and Witjes JA. (2008). Urinary markers in bladder cancer. Eur Urol 53, 909-916.